The use of prostate-specific antigen mass ratio in prostate cancer

Aim: Our goal in this study is to investigate the use and advantage of prostate-specific antigen mass ratio (PSAMR) in prostate cancer. Material and Methods: Data of patients who underwent prostate biopsy were reviewed prospectively. Body mass index and PSAMR were calculated using height, weight, prostate-specific antigen (PSA) and prostate volume. Patients were divided into benign and prostate cancer. Subgroups were formed according to body mass index. The area under the curve of PSAMR was compared with PSA. Results: One hundred seventy-one patients were included in the study; 72% of patients were benign and 28% were prostate cancer; 45% of patients were overweight and 20% were obese. PSAMR cut-off value was calculated as 0.37 mu g/mL. PSAMR was statistically significant higher than PSA in all patients and subgroups for prostate cancer in area under the curve of receiver operating characteristic analysis. Discussion: PSAMR avoids unnecessary biopsy by 42%. Especially in overweight and obese patients, PSAMR was found to be statistically significant than PSA for indication of biopsy and prostate cancer diagnosis. This study is the only one in the literature with a high obesity rate.